Nimustine (CAS 42471-28-3) Suppliers and Product Information

Nimustine is an organochlorine compound derived from urea. It is an antineoplastic agent particularly effective against malignant brain tumors. The compound is a pale yellow crystalline solid with a decomposition point of 125°C. It is classified as hazardous, with risk statements 25 and safety statements 36, 37, 39, and 45.

Nimustine can be synthesized by reacting 1-(2-chloroethyl)-3-[(2-methyl-4-aminopyridin-5-yl)methyl]urea with sodium nitrite in hydrochloric acid, followed by alkalinization with sodium carbonate and recrystallization from ethanol.

Frequently Asked Questions about Nimustine

Q: What is the main therapeutic use of Nimustine?

A: Nimustine is primarily used as an antitumor and antileukemic agent, with particular effectiveness against malignant brain tumors.

Q: What are some common synonyms for Nimustine?

A: Nimustine is also known as ACNU, Nidran, pimustine hydrochloride, and 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride.

Q: How is Nimustine typically packaged and supplied?

A: Nimustine is usually supplied in various quantities ranging from 50 mg to 5 kg, with common package sizes including 1g, 100mg, 200mg, 500mg, and 1kg. It is typically provided as a reagent for laboratory use only.

Q: What is the purity range for commercially available Nimustine?

A: The purity of commercially available Nimustine typically ranges from 85.0% to 99.9%, with many suppliers offering purities of 99% or higher.